Roivant Sciences Ltd. (NASDAQ:ROIV) COO Eric Venker sells 16,530 shares

Roivant Sciences Ltd. (NASDAQ:ROIV – Get Rating) COO Eric Venker sold 16,530 shares of Roivant Sciences in a trade dated Wednesday, August 24. The stock was sold at an average price of $3.71, for a total value of $61,326.30. Following the completion of the sale, the COO now owns 1,083,164 shares of the company, valued at $4,018,538.44. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Eric Venker also recently made the following trade(s):

  • On Monday July 25, Eric Venker sold 16,896 Roivant Sciences shares. The stock was sold at an average price of $4.33, for a total value of $73,159.68.
  • On Thursday June 23, Eric Venker sold 16,402 Roivant Sciences shares. The stock was sold at an average price of $4.34, for a total value of $71,184.68.

Roivant Sciences is trading down 5.5%

Shares of ROIV were down $0.22 in Friday trading, hitting $3.75. 627,929 shares of the stock traded in hands, compared to its average volume of 663,933. The company has a market capitalization of $2.63 billion, a P/E ratio of -2.34 and a beta of 1.33. The company has a debt ratio of 0.22, a current ratio of 6.20 and a quick ratio of 6.20. The company’s fifty-day moving average price is $4.24 and its 200-day moving average price is $4.55. Roivant Sciences Ltd. has a 52-week low of $2.52 and a 52-week high of $16.76.

pixel

A d Tradewins

The safest option in the trades!

If you’re new to trading, you’ve probably heard the wrong word about options, that they’re risky, unpredictable, or difficult. And it couldn’t be more wrong! With the Hughes Optioneering strategy, you will soon learn that the safest option for new accounts is the options themselves!

Roivant Sciences (NASDAQ:ROIV – Get Rating) last announced its results on Tuesday, June 28. The company reported ($0.39) earnings per share (EPS) for the quarter, missing analyst consensus estimates of ($0.25) by ($0.14). The company posted revenue of $9.22 million in the quarter, compared to $11.94 million expected by analysts. Roivant Sciences had a negative net margin of 2,110.83% and a negative return on equity of 68.61%. As a group, research analysts predict that Roivant Sciences Ltd. will show -1.71 earnings per share for the current fiscal year.

Analysts set new price targets

Several brokerages have recently weighed in on ROIV. Citigroup raised its price target on Roivant Sciences from $9.00 to $10.00 and gave the stock a “buy” rating in a Tuesday, August 16 report. HC Wainwright restated a “buy” rating and set a target price of $14.00 on shares of Roivant Sciences in a Thursday, June 30 report. SVB Leerink raised its price target on Roivant Sciences from $6.00 to $7.00 and gave the stock an “outperform” rating in a Wednesday, June 29 report. Cantor Fitzgerald took cover for Roivant Sciences in a Friday, April 29 report. They set an “overweight” rating and a target price of $15.00 on the stock. Finally, Goldman Sachs Group cut its price target on Roivant Sciences shares from $15.00 to $12.00 and set a “buy” rating on the stock in a Tuesday, May 24 research report. Eight equity research analysts rated the stock with a buy rating. According to data from MarketBeat, Roivant Sciences currently has a consensus rating of “Buy” and a consensus target price of $11.86.

Roivant Sciences Institutional Trading

A number of institutional investors and hedge funds have recently increased or reduced their stake in the company. SB Investment Advisers UK Ltd. acquired a new stake in Roivant Sciences in the fourth quarter, valued at approximately $1,001,706,000. BlackRock Inc. increased its position in Roivant Sciences by 3.0% in the first quarter. BlackRock Inc. now owns 4,044,419 shares of the company valued at $19,980,000 after purchasing an additional 117,329 shares during the period. Two Seas Capital LP increased its position in Roivant Sciences by 323.8% in the second quarter. Two Seas Capital LP now owns 3,419,836 shares of the company valued at $13,919,000 after purchasing an additional 2,612,929 shares during the period. American International Group Inc. acquired a new stake in Roivant Sciences in the first quarter valued at approximately $8,965,000. Finally, Eventide Asset Management LLC increased its position in Roivant Sciences by 141.5% in the first quarter. Eventide Asset Management LLC now owns 1,690,300 shares of the company valued at $8,177,000 after purchasing an additional 990,300 shares during the period. Hedge funds and other institutional investors hold 61.49% of the company’s shares.

About Roivant Sciences

(Get an evaluation)

Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops drugs. The company is developing product candidates for the treatment of various therapeutics, including solid tumors, sickle cell disease, hypophosphatasia, oncological malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis severe, autoimmune warm hemolytic anemia, thyroid eye disease, sarcoidosis, and Staphylococcus aureus bacteremia.

Featured Articles

Insider buying and selling by quarter for Roivant Sciences (NASDAQ:ROIV)

This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]

Before you consider Roivant Sciences, you’ll want to hear this.

MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes off…and Roivant Sciences didn’t make the list.

While Roivant Sciences currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.

See the five actions here

Comments are closed.